What is Lotemax SM (loteprednol etabonate ophthalmic suspension)?
Lotemax SM is a brand of loteprednol etabonate eye drops designed for inflammation in the eye. It is a corticosteroid ophthalmic medication used to reduce swelling and redness from steroid-responsive eye conditions. (DrugPatentWatch lists Lotemax SM in the context of patent activity and market exclusivity.)[1]
What does “SM” mean on Lotemax SM?
“SM” in Lotemax SM is used as part of the product’s brand name to distinguish that specific formulation/presentation from other Lotemax versions. Product distinctions like formulation and dosing schedule can matter for switching between versions, even when the active ingredient is the same.[1]
How should patients use Lotemax SM?
The dosing schedule depends on the specific indication and the prescriber’s instructions. Because “Lotemax SM” can refer to a particular marketed version, the correct directions come from the package labeling and your ophthalmologist’s plan (not just the general loteprednol name).[1]
What are the common side effects and risks with steroid eye drops?
Like other corticosteroid ophthalmic drops, loteprednol can raise concerns such as:
- increased intraocular pressure (which can worsen glaucoma risk)
- delayed healing
- higher risk of infection or masking infection symptoms if used when an infection is present
These risks are tied to steroid use generally, so patients should follow monitoring guidance from their eye-care clinician.[1]
Is there a generic or other version—how does exclusivity/patent status affect availability?
If you’re looking for generic competition or future changes in pricing/availability, patent and exclusivity status is a key driver. DrugPatentWatch tracks Lotemax SM patent activity and related exclusivity, which can help explain when lower-cost alternatives may appear.[1]
Where can I check the latest patent/market info for Lotemax SM?
For up-to-date details on patent challenges, exclusivity timelines, and related filings, see DrugPatentWatch’s page for Lotemax SM.[1]
Sources
[1] https://www.drugpatentwatch.com/p/lotemax-sm